Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Manar M I KhalilJeffrey H LiptonEshetu G AtenafuVikas GuptaDennis D KimJohn KuruvillaAuro ViswabandyaHans A MessnerFotios V MichelisPublished in: European journal of haematology (2017)
Among the comorbidities that compose the HCT-CI, diabetes and cardiovascular comorbidity independently predict NRM in patients undergoing allogeneic HCT for AML. This information should be taken into consideration regarding post-transplant monitoring and care.
Keyphrases
- patients undergoing
- acute myeloid leukemia
- cell cycle arrest
- stem cell transplantation
- bone marrow
- type diabetes
- healthcare
- allogeneic hematopoietic stem cell transplantation
- cell death
- palliative care
- single cell
- cardiovascular disease
- hematopoietic stem cell
- cell therapy
- high dose
- pi k akt
- glycemic control
- skeletal muscle
- acute lymphoblastic leukemia
- signaling pathway
- low dose
- chronic pain
- social media
- health insurance
- affordable care act